NEW YORK (GenomeWeb) – Admera Health recently expanded the number of genes covered in its next-gen sequencing liquid biopsy assay, making it possible for the company to give a readout of microsatellite instability (MSI), which has become a crucial biomarker for cancer immunotherapies such as Merck's PD-1/PD-L1 inhibitor Keytruda (pembrolizumab).
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.